# Endometrial Neoplasms trials: 261 new since Nov 2024

Updated November 4, 2026.

261 clinical studies in Endometrial Neoplasms were first posted on ClinicalTrials.gov from November 13, 2024 to November 4, 2026; 91 have an industry sponsor and 220 are recruiting or about to. The newest, NCT07916610, was posted on November 4, 2026: Comparison of Superficial-Only Versus Combined Indocyanine Green Injection Techniques for Sentinel Lymph Node... (Barretos Cancer Hospital).

## The full list

New Endometrial Neoplasms clinical trials: 261 rows for $13.05, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 13 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/endometrial-neoplasms

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 261
- Industry sponsored: 91
- Recruiting or not yet: 220
- Latest posted: November 4, 2026

## Newest trials

The newest 100 of 261, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 4, 2026 | NCT07916610 | Comparison of Superficial-Only Versus Combined Indocyanine Green Injection Techniques for Sentinel Lymph Node Mapping in Patients With... | Barretos Cancer Hospital | Not applicable | Not yet recruiting | Endometrial Cancer | 200 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916610) |
| November 2, 2026 | NCT07909031 | CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Crescent Biopharma, Inc. | Phase 1/2 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC)... | 219 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909031) |
| October 28, 2026 | NCT07902375 | Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers | Universiteit Antwerpen | Not applicable | Recruiting | Gynaecological Cancers, Ovarian Cancer, Endometrial Cancer, Vulvar Cancer, Vaginal Cancer, Postmenopausal Bleeding... | 730 | Belgium | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902375) |
| October 28, 2026 | NCT07900256 | A Preliminary Exploratory Study of Cadonilimab Combined With Progestin for Fertility-Sparing Treatment in Early Endometrial Cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | Not yet recruiting | Endometrial Cancer | 10 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900256) |
| October 27, 2026 | NCT07896720 | Remote Robotic Surgery for Gynecologic Cancer: A Safety and Effectiveness Study | Women's Hospital School Of Medicine Zhejiang University | Not applicable | Not yet recruiting | Endometrial Cancer, Cervical Cancer (Early Detection) | 92 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896720) |
| October 26, 2026 | NCT07895212 | Feasibility of the "One-Finger Technique" for Identifying the Upper Left Ureter During Para-Aortic Lymphadenectomy | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not applicable | Recruiting | Ovary Cancer, Cervical Cancer, Endometrial Cancer | 40 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895212) |
| October 23, 2026 | NCT07892755 | Liquid Biopsy-Based Early Screening for Endometrial Cancer in Regional Chinese Populations | Guizhou Provincial People's Hospital | Observational | Recruiting | Endometrial Cancer, Atypical Endometrial Hyperplasia | 512 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892755) |
| October 20, 2026 | NCT07883798 | Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic Lesions | Affidea Nu-med Center of Oncological DIagnostics and Therapy | Observational | Recruiting | Cervical Cancer, Gynecologic Cancer, Endometrial Cancer, Uterine Cancer, Uterine Sarcoma, Ovarian Cancer, Fallopian... | 500 | Poland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883798) |
| October 20, 2026 | NCT07882277 | 27-Inch Versus 55-Inch Monitors in Women Undergoing Endometrial Cancer Surgery | Metehan Uzundal | Not applicable | Not yet recruiting | Endometrial Cancer | 70 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882277) |
| October 16, 2026 | NCT07879365 | Effect of Weight Management on AMPK Activation in the Adjunctive Treatment of Endometrial Cancer | Peking University People's Hospital | Not applicable | Not yet recruiting | Endometrial Cancer | 160 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07879365) |
| October 16, 2026 | NCT07877779 | Protocol for Non-invasive Gynaecological Surveillance in Lynch Syndrome | University of Edinburgh | Observational | Not yet recruiting | Lynch Syndrome | 1,450 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877779) |
| October 15, 2026 | NCT07874880 | MTX-531-001 Phase 1 Study in Advanced Solid Tumors | MEKanistic Therapeutics, Inc. | Phase 1 | Not yet recruiting | Solid Tumors (Phase 1), HNSCC, Endometrial Cancer, Her2-negative Metastatic Breast Cancer, Pan-RAS and BRAF Wild-type... | 71 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874880) |
| October 15, 2026 | NCT07874529 | Cervical Cytology DNA Methylation for Endometrial Cancer Screening | Lei Li | Observational | Active not recruiting | Endometrial Cancer, DNA Methylation, Cytology, Cancer Screening | 30,000 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874529) |
| October 13, 2026 | NCT07871838 | Safety, Efficacy and Quality of Life After Adjuvant Hypofractionated Radiotherapy for Endometrial Cancer | McGill University Health Centre/Research Institute of the McGill University Health Centre | Not applicable | Recruiting | Endometrial Cancer, Endometrial Adenocarcinoma | 50 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871838) |
| October 13, 2026 | NCT07870278 | A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001) | Merck Sharp & Dohme LLC | Phase 1 | Not yet recruiting | Ovarian Neoplasms, Endometrial Neoplasms | 80 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07870278) |
| October 9, 2026 | NCT07867002 | Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer | UNC Lineberger Comprehensive Cancer Center | Phase 3 | Recruiting | Endometrial Adenocarcinoma, Metastatic Endometrial Cancer, Endometrial Cancer, Recurrent Endometrial Cancer | 140 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867002) |
| October 8, 2026 | NCT07865650 | PEG-rhG-CSF Primary Prophylaxis vs Therapeutic Short-Acting rhG-CSF for Neutropenia During Pelvic Chemoradiotherapy in Cervical or... | The Second Hospital of Anhui Medical University | Not applicable | Active not recruiting | Cervical Cancer, Endometrial Cancer | 90 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07865650) |
| October 6, 2026 | NCT07860450 | Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent... | GlaxoSmithKline | Phase 3 | Not yet recruiting | Endometrial Carcinoma, Neoplasms, Endometrial | 378 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07860450) |
| October 6, 2026 | NCT07860203 | Stellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery | Catherin Zhang | Not applicable | Recruiting | Uterine Fibroids (Leiomyoma), Adenomyosis of Uterus, Endometriosis, Endometrial Cancer, Cervical Cancer, Ovarian Cancer | 100 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07860203) |
| September 24, 2026 | NCT07838207 | Prognosis and Therapeutic Implications in Molecular High-Risk Non-Myoinvasive Endometrial Cancer | Hospital Universitari Vall d'Hebron Research Institute | Observational | Recruiting | Endometrial Cancer, Endometrial Carcinoma (EC), p53abn | 350 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07838207) |
| September 21, 2026 | NCT07832227 | Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial | Dana-Farber Cancer Institute | Phase 2 | Not yet recruiting | Low Grade Ovarian Serous Adenocarcinoma, Endometrial Cancer | 60 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832227) |
| September 21, 2026 | NCT07831902 | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With... | University College, London | Phase 3 | Recruiting | Endometrial Cancer, Uterine Neoplasms | 600 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07831902) |
| September 16, 2026 | NCT07821775 | Robotic vs Laparoscopic and Open Surgery for Abdominopelvic Cancers | Asan Medical Center | Observational | Completed | Pancreatic Neoplasms, Stomach Neoplasms, Rectal Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Kidney... | 32,949 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07821775) |
| September 15, 2026 | NCT07820358 | Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer | The Methodist Hospital Research Institute | Phase 2 | Not yet recruiting | Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial... | 48 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07820358) |
| September 11, 2026 | NCT07815951 | Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors | Yong He | Phase 1 | Not yet recruiting | Solid Tumors, Carcinoma, Ovarian Neoplasms, Endometrial Neoplasms Malignant, Testicular Neoplasms, Lung Neoplasms... | 8 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07815951) |
| September 11, 2026 | NCT07815873 | Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers | European Institute of Oncology | Not applicable | Not yet recruiting | Non Small Cell Lung Cancer, Melanoma (Skin Cancer), Endometrial Cancer, Cervical Cancer | 360 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07815873) |
| September 11, 2026 | NCT07814872 | A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment | Harvard Medical School (HMS and HSDM) | Observational | Not yet recruiting | Neoplasms (Cancer / Tumors), Colorectal Neoplasms, Lung Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Pancreatic... | 30,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814872) |
| September 10, 2026 | NCT07814248 | A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a... | TwoStep Therapeutics, Inc. | Phase 1 | Recruiting | NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer, Esophageal Cancer, Head & Neck Cancer, Gastric... | 74 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814248) |
| September 10, 2026 | NCT07811297 | A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | Advenchen Pharmaceuticals, LLC. | Phase 1/2 | Not yet recruiting | Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma | 138 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811297) |
| September 10, 2026 | NCT07811232 | A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers | Advenchen Pharmaceuticals, LLC. | Phase 1/2 | Not yet recruiting | Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms | 138 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811232) |
| September 8, 2026 | NCT07808164 | ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort | Tam Anh Research Institute | Observational | Recruiting | HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Gastric Carcinoma, Breast Cancer, Lung Cancer, Endometrial... | 162 | Vietnam | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808164) |
| September 8, 2026 | NCT07807345 | Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic | Sutro Biopharma, Inc. | Phase 1 | Recruiting | Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Colorectal Cancer... | 285 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807345) |
| August 28, 2026 | NCT07793318 | TR115 in ARID1A-Mutated Advanced Solid Tumors | Tarapeutics Science Inc. | Phase 2 | Not yet recruiting | Ovarian Clear Cell Carcinoma, Endometrial Cancer, Stomach Cancer Recurrent, Urinary Bladder Cancer | 50 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07793318) |
| August 24, 2026 | NCT07781150 | Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer | Tongji Hospital | Phase 2 | Not yet recruiting | Obesity, Overweight, Atypical Endometrial Hyperplasia, Endometrial Carcinoma Stage I, Endometrioid Endometrial Cancer | 128 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781150) |
| August 21, 2026 | NCT07779109 | Pelvic Ultra-Hypofractionated Adjuvant Radiotherapy for Endometrial Cancer (PURE-cohort) | Instituto de Investigación Sanitaria Aragón | Not applicable | Recruiting | SBRT, Radiation Therapy, Endometrial Cancer, Endometrial Cancer Stage III, High-risk Endometrial Cancer | 50 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07779109) |
| August 10, 2026 | NCT07755436 | Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic... | ArriVent BioPharma, Inc. | Phase 1 | Recruiting | Ovarian Cancer, Endometrial Cancer, Platinum-resistant Ovarian Cancer (PROC), Metastatic Ovarian Cancer, Metastatic... | 180 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07755436) |
| August 7, 2026 | NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | LG Chem | Phase 1/2 | Not yet recruiting | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast... | 250 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752875) |
| August 4, 2026 | NCT07746024 | Advancing Risk Stratification in Endometrial Cancer | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Observational | Active not recruiting | Endometrial Cancer | 400 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07746024) |
| August 4, 2026 | NCT07743541 | Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy | Gilead Sciences | Phase 1/2 | Not yet recruiting | Uterine Endometrial Cancer | 100 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743541) |
| August 3, 2026 | NCT07741968 | A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer | City of Hope Medical Center | Not applicable | Recruiting | Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC... | 126 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07741968) |
| July 31, 2026 | NCT07739745 | Development Of An Endometrial Cancer Educational Tool | M.D. Anderson Cancer Center | Not applicable | Not yet recruiting | Endometrial Cancer | 250 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07739745) |
| July 31, 2026 | NCT07738315 | Elemene Liposomes in Endometrial Cancer | Women's Hospital School Of Medicine Zhejiang University | Phase 2 | Not yet recruiting | Endometrial Carcinoma | 212 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07738315) |
| July 30, 2026 | NCT07737795 | Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer | University of Oklahoma | Phase 2 | Not yet recruiting | Endometrial Cancer | 66 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07737795) |
| July 28, 2026 | NCT07731607 | Sintilimab Monotherapy in Patients With Stage I-II MSI-H/dMMR Endometrial Cancer | Wang Jianliu | Phase 2 | Not yet recruiting | MMRd Endometrial Cancer of Stage I~II | 48 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07731607) |
| July 24, 2026 | NCT07725159 | Comparison of Lee-Huang Point and Umbilical Entry for Laparoscopic Success in Endometrial Cancer Patients | Dr. Lutfi Kirdar Kartal Training and Research Hospital | Not applicable | Completed | Endometrial Cancer | 202 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07725159) |
| July 23, 2026 | NCT07723235 | Web-based Lifestyle Program, mHealth and EMA Intervention, to Improve Weight Loss in Rural Stage I-III Postmenopausal Breast and... | Ohio State University Comprehensive Cancer Center | Not applicable | Not yet recruiting | Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC... | 90 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07723235) |
| July 20, 2026 | NCT07715747 | A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors | TJ Biopharma Co., Ltd. | Phase 1 | Recruiting | Solid Tumor, Metastatic Ovary Cancer, Metastatic Gastric Cancer, Metastatic Endometrial Carcinoma | 128 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715747) |
| July 20, 2026 | NCT07714070 | Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia | Peking University People's Hospital | Phase 2 | Not yet recruiting | Endometrial Neoplasms, Endometrial Cancer, Atypical Endometrial Hyperplasia, Progestin Resistance | 48 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07714070) |
| July 14, 2026 | NCT07702799 | Low-Residue Diet Versus Rectal Enema Before Laparoscopic Surgery for Endometrial Cancer | Mahmut Yassa | Not applicable | Recruiting | Endometrial Cancer | 100 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07702799) |
| July 14, 2026 | NCT07702721 | Intraoperative Microscopic Assessment of Lymph Node Status in Gynecological Malignancies | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Observational | Not yet recruiting | Gynecologic Cancer, Cervical Cancer, Endometrial Cancer, Ovary Cancer, Vulvar Cancer | 160 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07702721) |
| July 8, 2026 | NCT07690540 | DETERMINANTS OF IMMUNOTHERAPY EFFICACY IN ENDOMETRIAL CANCER | European Institute of Oncology | Not applicable | Recruiting | Endometrial Cancer, Immune Checkpoint Inhibitors | 510 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07690540) |
| July 6, 2026 | NCT07684599 | A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02) | GlaxoSmithKline | Phase 3 | Recruiting | Neoplasms, Endometrial | 610 | Canada, Japan, South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684599) |
| July 2, 2026 | NCT07681414 | ctDNA Assessment in Endometrial Cancer for Adjuvant Therapy | Guizhou Provincial People's Hospital | Observational | Active not recruiting | Endometrial Cancer | 52 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07681414) |
| June 30, 2026 | NCT07675733 | A Study of Short-course Hypofractionated Online-adaptive Radiotherapy for the Post-operative Treatment of Endometrial Cancer: Tolerability... | Royal Marsden NHS Foundation Trust | Not applicable | Recruiting | Endometrial Carcinoma (EC) | 30 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07675733) |
| June 24, 2026 | NCT07664735 | A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. | Outpace Bio, Inc. | Phase 1 | Recruiting | Endometrial Cancer Recurrent, Endometrial Cancer, Advanced Endometrial Cancer, Ovarian Cancer, Ovarian Cancer... | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07664735) |
| June 23, 2026 | NCT07662824 | Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy | Mayo Clinic | Not applicable | Recruiting | Cervical Carcinoma, Endometrial Carcinoma, Overactive Bladder, Voiding Disorders | 44 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662824) |
| June 17, 2026 | NCT07652515 | A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer | GlaxoSmithKline | Phase 4 | Not yet recruiting | Neoplasms, Endometrial | 100 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07652515) |
| June 11, 2026 | NCT07643012 | Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer | Rutgers, The State University of New Jersey | Not applicable | Recruiting | Endometrial Cancer | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07643012) |
| June 10, 2026 | NCT07639801 | 68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors | Peking University Cancer Hospital & Institute | Not applicable | Not yet recruiting | Prostate Cancer, Hepatocellular Carcinoma, Ovarian Cancer, Solid Tumors, Endometrial Cancer, FAPI, PSMA | 20 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07639801) |
| June 9, 2026 | NCT07634601 | Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer | Jonsson Comprehensive Cancer Center | Phase 2 | Not yet recruiting | Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Stage III... | 50 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07634601) |
| June 8, 2026 | NCT07631884 | Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor | Haihua Yuan | Phase 2 | Not yet recruiting | Solid Tumors, Neoplasms (Cancer / Tumors), Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid... | 15 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631884) |
| June 8, 2026 | NCT07631871 | An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy | Haihua Yuan | Phase 2 | Not yet recruiting | Neoplasms, Solid Tumors, HER2 Positive Solid Tumor, Endometrial Neoplasm, Urothelial Carcinoma (UC), Pancreatic... | 10 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631871) |
| June 3, 2026 | NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | Huahui Health | Phase 1 | Recruiting | Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Head and Neck Squamous Cell... | 299 | Australia, China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623369) |
| June 3, 2026 | NCT07622901 | Fasting InTervention for Endometrial Cancer | University of Miami | Not applicable | Recruiting | Endometrial Cancer | 42 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07622901) |
| May 29, 2026 | NCT07612891 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With... | Shenzhen Ionova Life Sciences Co., Ltd. | Phase 1/2 | Recruiting | Breast Cancer (Locally Advanced or Metastatic), Advanced Solid Cancers, Metastatic (Stage IV) Breast Cancer, Ovarian... | 201 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07612891) |
| May 28, 2026 | NCT07610798 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced... | Shenzhen Ionova Life Sciences Co., Ltd. | Phase 1/2 | Recruiting | Advance Solid Tumors, Colon and Rectal Cancer, Non - Small Cell Lung Cancer NSCLC, Pancreatic Adenocarcinoma Advanced... | 178 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07610798) |
| May 22, 2026 | NCT07605247 | Tirzepatide in the Treatment of Endometrial Cancer | Rutgers, The State University of New Jersey | Phase 2 | Not yet recruiting | Endometrial Cancer | 30 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07605247) |
| May 19, 2026 | NCT07595224 | Postoperative Hypofractionated Whole Pelvic Radiotherapy in Cervical and Endometrial Cancer | Siriraj Hospital | Not applicable | Recruiting | Endometrial Cancer, Cervix Cancer | 120 | Thailand | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07595224) |
| May 18, 2026 | NCT07594327 | Quality of Life and Sexuality After Pelvic Exenteration for Gynecologic Cancer | Tampere University Hospital | Observational | Enrolling by invitation | Cervical Cancers, Vaginal Cancers, Vulvar Cancers, Endometrial Cancer, Gynecologic Cancers | 21 | Finland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07594327) |
| May 18, 2026 | NCT07594015 | Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line... | University of Miami | Phase 2 | Recruiting | Recurrent Endometrial Cancer | 46 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07594015) |
| May 14, 2026 | NCT07586826 | Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or... | Peking University People's Hospital | Phase 2 | Recruiting | Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gynecologic Cancers... | 220 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07586826) |
| May 13, 2026 | NCT07584161 | MH-ART vs CF-IMRT in Postoperative Cervical/Endometrial Cancer | Xiaorong Hou | Not applicable | Recruiting | Cervical Cancer, Endometrial Cancer | 228 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07584161) |
| May 13, 2026 | NCT07583329 | Comparison of Sentinel Lymph Node Applications in Endometrial Cancer Cases Performed With Vaginal Natural Orifice Transluminal Endoscopic... | Cukurova University | Observational | Not yet recruiting | Endometrial Adenocarcinoma, Endometrial Cancer | 160 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583329) |
| May 12, 2026 | NCT07581288 | Measurement of Urinary Hormones in Patients With Abnormal Uterine Bleeding to Study Uterine Cancer Progression | University of British Columbia | Observational | Not yet recruiting | Uterine Bleeding, Uterine Cancer, Uterine Neoplasms, Endometrial Cancer, Endometrial Hyperplasia, Endometrial... | 50 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07581288) |
| May 11, 2026 | NCT07578649 | Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With... | Pfizer | Phase 3 | Recruiting | Endometrial Neoplasms, Endometrial Cancer | 600 | Australia, China, Japan, Taiwan, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07578649) |
| April 30, 2026 | NCT07558889 | The Surveillance, Epidemiology, and End Results Database Program on Endometrial Cancer in the Italian Population | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Observational | Recruiting | Endometrium Cancer, Gynecologic Cancer | 10,000 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07558889) |
| April 29, 2026 | NCT07557225 | 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors | Peking University First Hospital | Not applicable | Recruiting | Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC), Colorectal Cancer, Cervical Cancer, Ovarian Cancer... | 200 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07557225) |
| April 29, 2026 | NCT07555665 | REal Word aPpLicAtion of Molecular Based Endometrial Cancer Classification | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Observational | Recruiting | Endometrial Cancer | 264 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07555665) |
| April 22, 2026 | NCT07544680 | Endometrial Cancer Vaginal Fluid Specimen Collection Study | Exact Sciences Corporation | Observational | Active not recruiting | Abnormal Uterine Bleeding (AUB), Endometrial Cancer, Atypical Endometrial Hyperplasia, Endometrial Hyperplasia With... | 4,200 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07544680) |
| April 14, 2026 | NCT07527143 | Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer | Mayo Clinic | Observational | Recruiting | Endometrial Carcinoma | 25 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07527143) |
| April 13, 2026 | NCT07524322 | Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors | Regor Pharmaceuticals Inc. | Phase 1 | Recruiting | Breast Cancer, Ovarian Cancer, Endometrial Cancer, PIK3CA Mutation, HER2- Negative Breast Cancer, Advanced Breast... | 63 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07524322) |
| April 13, 2026 | NCT07522697 | Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4 | National Cancer Institute, Naples | Phase 2 | Not yet recruiting | Endometrial Cancer | 48 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07522697) |
| April 7, 2026 | NCT07516210 | Adaptive Radiotherapy for Safe Hypofractionation | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 2 | Not yet recruiting | Cancer, Endometrial Cancer, Prostate Cancer, Cervical Cancer, Rectal Cancers | 264 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516210) |
| April 7, 2026 | NCT07514325 | MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer | Radboud University Medical Center | Not applicable | Not yet recruiting | Endometrial Cancer, Radiotherapy, Adjuvant | 61 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07514325) |
| March 31, 2026 | NCT07503808 | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types | IDEAYA Biosciences | Phase 1 | Recruiting | Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal... | 150 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07503808) |
| March 13, 2026 | NCT07470853 | A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. | Whitehawk Therapeutics, Inc. | Phase 1 | Recruiting | PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer | 265 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07470853) |
| March 10, 2026 | NCT07462663 | SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage... | Hospital Universitari de Bellvitge | Phase 4 | Not yet recruiting | Endometrial Cancer, Endometrial Cancer Stage I, Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I... | 80 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07462663) |
| March 9, 2026 | NCT07458347 | A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral... | Kestrel Therapeutics, Inc. | Phase 1 | Recruiting | KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant... | 545 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07458347) |
| March 6, 2026 | NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | Qilu Pharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer, Advanced Solid Tumors, Ovarian Cancer | 626 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07453394) |
| March 3, 2026 | NCT07446049 | A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the... | Convalife (Shanghai) Co., Ltd. | Phase 2 | Not yet recruiting | Locally Advanced or Metastatic Solid Tumors, PTEN Loss or Low Expression | 180 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07446049) |
| March 3, 2026 | NCT07444814 | Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors | Whitehawk Therapeutics, Inc. | Phase 1 | Recruiting | Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent, Non-squamous EGFR... | 226 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07444814) |
| February 27, 2026 | NCT07435623 | Late Radiation Toxicities in Cervical and Endometrial Cancer: A Postoperative IMRT/Brachytherapy Study | Tata Memorial Hospital | Observational | Recruiting | Endometrial Cancer, Cervix Cancer | 300 | India | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07435623) |
| February 24, 2026 | NCT07429799 | An Exploratory Study of Detection of Endometrial and Ovarian Cancers in Vaginal Samples Retrieved by the Ellele Sampling Device | Ellele Health | Not applicable | Not yet recruiting | Ovarian Cancer, Endometrial Cancer | 300 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07429799) |
| February 19, 2026 | NCT07419841 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 | Compass Therapeutics | Phase 1 | Recruiting | Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC) | 70 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07419841) |
| February 12, 2026 | NCT07407959 | Screening and Staging of Benign vs Malignant Pelvic Abnormalities | Mayo Clinic | Observational | Recruiting | Endometrial Carcinoma, Prostate Carcinoma | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07407959) |
| February 12, 2026 | NCT07406087 | Navigation Intervention for Adolescent and Young Adult Cancer Survivors | Kaiser Permanente | Not applicable | Recruiting | Breast Cancer, Ovarian Cancer, Cervical Cancer, Testicular Cancer, Colon Rectal Cancer, Melanoma (Skin Cancer)... | 25 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07406087) |
| February 10, 2026 | NCT07400835 | Evaluation of DNA Methylation Markers for Endometrial Cancer Risk-stratification Using Patient-collected Urine and Vaginal Samples and... | University of Aarhus | Observational | Recruiting | Postmenopausal Bleeding | 600 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07400835) |
| February 9, 2026 | NCT07397624 | Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer | Centro di Riferimento Oncologico - Aviano | Observational | Recruiting | Endometrial Cancer | 74 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07397624) |
| February 3, 2026 | NCT07383506 | A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors | Cogent Biosciences, Inc. | Phase 1 | Recruiting | PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2-low... | 90 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07383506) |
| February 3, 2026 | NCT07382583 | Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention... | M.D. Anderson Cancer Center | Observational | Recruiting | Levonorgestrel, Intrauterine Systems, Prevention, Endometrial Cancer | 270 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07382583) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 10 | August 4, 2026 |
| GlaxoSmithKline | 8 | October 6, 2026 |
| AstraZeneca | 8 | August 15, 2025 |
| Peking University People's Hospital | 6 | October 16, 2026 |
| Mayo Clinic | 6 | June 23, 2026 |
| Memorial Sloan Kettering Cancer Center | 5 | January 6, 2026 |
| UNC Lineberger Comprehensive Cancer Center | 4 | October 9, 2026 |
| European Institute of Oncology | 4 | September 11, 2026 |
| National Cancer Institute, Naples | 4 | April 13, 2026 |
| Women's Hospital School Of Medicine Zhejiang University | 3 | October 27, 2026 |
| Rutgers, The State University of New Jersey | 3 | June 11, 2026 |
| Peking Union Medical College Hospital | 3 | December 23, 2025 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2 | October 28, 2026 |
| Guizhou Provincial People's Hospital | 2 | October 23, 2026 |
| Merck Sharp & Dohme LLC | 2 | October 13, 2026 |
| University College, London | 2 | September 21, 2026 |
| Asan Medical Center | 2 | September 16, 2026 |
| Advenchen Pharmaceuticals, LLC. | 2 | September 10, 2026 |
| Sutro Biopharma, Inc. | 2 | September 8, 2026 |
| Tongji Hospital | 2 | August 24, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 69 | November 4, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 64 | October 23, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 41 | October 28, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 35 | October 15, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 24 | November 2, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 15 | October 9, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 6 | June 17, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 5 | January 5, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 2 | January 6, 2026 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 103 | November 2, 2026 |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 52 | October 26, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 35 | September 11, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 24 | September 24, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 18 | June 3, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 17 | September 16, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 16 | December 29, 2025 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 15 | October 13, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 15 | July 6, 2026 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 13 | October 20, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 13 | December 29, 2025 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 10 | October 28, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 10 | October 20, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 10 | October 16, 2026 |
| [Denmark](https://specstream.ai/data/clinical-trials/country/denmark) | 9 | February 10, 2026 |
| [Taiwan](https://specstream.ai/data/clinical-trials/country/taiwan) | 8 | May 11, 2026 |
| [Finland](https://specstream.ai/data/clinical-trials/country/finland) | 6 | May 18, 2026 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 6 | December 16, 2025 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 6 | October 9, 2025 |
| [Greece](https://specstream.ai/data/clinical-trials/country/greece) | 5 | January 5, 2026 |
| [Israel](https://specstream.ai/data/clinical-trials/country/israel) | 5 | December 16, 2025 |
| [Austria](https://specstream.ai/data/clinical-trials/country/austria) | 5 | December 3, 2025 |
| [Singapore](https://specstream.ai/data/clinical-trials/country/singapore) | 5 | December 3, 2025 |
| [Czechia](https://specstream.ai/data/clinical-trials/country/czechia) | 4 | January 26, 2026 |
| [Argentina](https://specstream.ai/data/clinical-trials/country/argentina) | 4 | December 16, 2025 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).